Clinical TrialJun 16, 2026, 08:46 AM
Propanc Biopharma Prepares for Phase 1b PRP Production with CDMO
AI Summary
Propanc Biopharma, Inc. announced that its CEO, James Nathanielsz, toured a European CDMO's GMP facility to prepare for the production of its lead asset, PRP. This production is crucial for the upcoming Phase 1b, First-In-Human study involving 30-40 advanced cancer patients with solid tumors. Key timelines include preproduction in August 2026, an engineering run in October 2026, and GMP manufacture commencing in December 2026, with a Phase 1B clinical trial application in Australia planned for submission in 2026.
Key Highlights
- Propanc Biopharma CEO toured European CDMO facility for PRP production.
- PRP is for Phase 1b First-In-Human study in 30-40 advanced cancer patients.
- Preproduction of PRP is targeted for August 2026.
- Engineering run for PRP is scheduled for October 2026.
- GMP manufacture of PRP is set to commence December 2026.
- Phase 1B clinical trial application in Australia planned for 2026.
- CDMO facility includes 1,400sqm for cGMP manufacturing.
Price Impact
More from PPCB